Belite Bio Inc ADR (BLTE) Stock Forecast & Price Target
Belite Bio Inc ADR · NASDAQ
$193.37-0.24 (-0.12%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Belite Bio Inc ADR, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $132.00 to $270.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $205.33 sits 6% above the current $193.37. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.93 next quarter toward $2.14 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Belite Bio Inc ADR.
As of Sep, 6 of 6 firms rate BLTE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BLTE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.93
Range $-1.43 – $-0.51 · 7 analysts · +32% YoY
Next period, 7 analysts expect Belite Bio Inc ADR to earn $-0.93 a share (range $-1.43 – $-0.51), versus $-0.70 a year earlier. Full-year consensus is $-2.95, growing to $2.14 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $264.7M next year.
Top analysts covering Belite Bio Inc ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BLTE.
#1
Yi Chen
HC Wainwright & Co. · Rank #277
Buy
$214.00+10.7% to target
Overall win rate
33%
+ Follow
#2
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$195.00+0.8% to target
Overall win rate
47%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #374
Buy
$217.00+12.2% to target
Overall win rate
36%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #428
Buy
$110.00-43.1% to target
Overall win rate
32%
+ Follow
#5
Judah Frommer
Morgan Stanley
Buy
$206.00+6.5% to target
Coverage
—
+ Follow
BLTE stock forecast FAQ
What is BLTE's average 12-month price target?+
The 6 analysts with a live target average $205.33 for Belite Bio Inc ADR over the next 12 months, ranging from a $270.00 high to a $132.00 low.
Is BLTE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BLTE?+
The Street-high target is $270.00 (Cantor Fitzgerald), and the Street-low is $132.00 (Benchmark). The average of all 6 active targets is $205.33.
How many Wall Street analysts cover BLTE?+
6 analysts have an active rating on Belite Bio Inc ADR, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering BLTE?+
Among analysts who currently cover BLTE, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #277). Their current call is Buy with a $214.00 target.
What is Belite Bio Inc ADR's projected EPS for next quarter?+
The consensus estimate is $-0.93 per share (range $-1.43 – $-0.51) across 7 analysts. Full-year EPS is projected at $-2.95, rising to $2.14 the following year.
How much revenue is Belite Bio Inc ADR expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $264.7M next year.
Have analysts been upgrading or downgrading BLTE lately?+
As of Sep, 6 of 6 firms rate BLTE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BLTE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
